Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
| Revenue (Most Recent Fiscal Year) | $5.17M |
| Net Income (Most Recent Fiscal Year) | $-18.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 16.71 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -9.07% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -25.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.12 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.49 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.20 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.29 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.83 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 36.19M |
| Free Float | 5.25M |
| Market Capitalization | $78.54M |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 0.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 85.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 3.57% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |